InSug O-Sullivan

Dr. InSug O-Sullivan

orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2000 in Biochemistry
Verified
Journal Article
Closed access
LOLaszlo Otvos
Laszlo Otvos
IOInSug O-Sullivan
InSug O-Sullivan
MRMark E. Rogers
Mark E. Rogers
PCPatricia J. Consolvo
Patricia J. Consolvo
BCBarry A. Condie
Barry A. Condie
MBMagdalena Blaszczyk-Thurin
Magdalena Blaszczyk-Thurin

12 May 2015 in Nature Communications
Verified
Journal Article
Open access
PDF file
IOInSug O-Sullivan
InSug O-Sullivan
WZWenwei Zhang
Wenwei Zhang
DWDavid H. Wasserman
David H. Wasserman
CLChong Wee Liew
Chong Wee Liew
JLJonathan Liu
Jonathan Liu
TUTerry G. Unterman
Terry G. Unterman
FoxO proteins are major targets of insulin action. To better define the role of FoxO1 in mediating insulin effects in the liver, we generated liver-specific insulin receptor knockout (LIRKO) and IR/FoxO1 double knockout (LIRFKO) mice. Here we show that LIRKO mice are severely insulin resistant based on glucose, insulin and C-peptide levels, and glucose and insulin tolerance tests, and genetic deletion of hepatic FoxO1 reverses these effects. 13C-glucose and insulin clamp studies indicate that regulation of both hepatic glucose production (HGP) and glucose utilization is impaired in LIRKO mice, and these defects are also restored in LIRFKO mice corresponding to changes in gene expression. We conclude that (1) inhibition of FoxO1 is critical for both direct (hepatic) and indirect effects of insulin on HGP and utilization, and (2) extrahepatic effects of insulin are sufficient to maintain normal whole-body and hepatic glucose metabolism when liver FoxO1 activity is disrupted.

1 June 2012 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
XDXiong Deng
Xiong Deng
WZWenwei Zhang
Wenwei Zhang
IOInSug O-Sullivan
InSug O-Sullivan
JWJ. Bradley Williams
J. Bradley Williams
QDQingming Dong
Qingming Dong
MEMarshall B. Elam
Marshall B. Elam
Induction of lipogenesis in response to insulin is critically dependent on the transcription factor, sterol regulatory element-binding protein-1c (SREBP-1c). FoxO1, a forkhead box class-O transcription factor, is an important mediator of insulin action, but its role in the regulation of lipid metabolism has not been clearly defined. We examined the effects of FoxO1 on srebp1 gene expression in vivo and in vitro. In vivo studies showed that constitutively active (CA) FoxO1 (CA-FoxO1) reduced basal expression of SREBP-1c mRNA in liver by ∼60% and blunted induction of SREBP-1c in response to feeding. In liver-specific FoxO knock-out mice, SREBP-1c expression was increased ∼2-fold. Similarly, in primary hepatocytes, CA-FoxO1 suppressed SREBP1-c expression and inhibited basal and insulin-induced SREBP-1c promoter activity. SREBP-1c gene expression is induced by the liver X receptor (LXR), but CA-FoxO1 did not block the activation of SREBP-1c by the LXR agonist TO9. Insulin stimulates SREBP-1c transcription through Sp1 and via “feed forward” regulation by newly synthesized SREBP-1c. CA-FoxO1 inhibited SREBP-1c by reducing the transactivational capacity of both Sp1 and SREBP-1c. In addition, chromatin immunoprecipitation assays indicate that FoxO1 can associate with the proximal promoter region of the srebp1 gene and disrupt the assembly of key components of the transcriptional complex of the SREBP-1c promoter. We conclude that FoxO1 inhibits SREBP-1c transcription via combined actions on multiple transcription factors and that this effect is exerted at least in part through reduced transcriptional activity of Sp1 and SREBP-1c and disrupted assembly of the transcriptional initiation complex on the SREBP-1c promoter.

1 December 1997 in Toxicology
Verified
Journal Article
Open access
IOInSug O-Sullivan
InSug O-Sullivan
SDSugandha Datar
Sugandha Datar
CKCameron J Koch
Cameron J Koch
ISIrving M Shapiro
Irving M Shapiro
BSBruce J Shenker
Bruce J Shenker
The focus of this investigation was to examine the effects of low concentrations of organic mercuric compounds on human monocyte function and to relate these effects to apoptosis. Following exposure of monocytes to 0-5 microM MeHgCl, phagocytic function and capacity to generate a respiratory burst, following PMA activation, were determined. We found that the mercury-treated cells exhibited reduced phagocytic activity. Exposure to the same mercury concentration range, also caused a marked increase in cell death. To ascertain if monocyte death was due to apoptosis, a number of flow cytometric studies were performed. Mercury-treated cells exhibited increased Hoechst 33258 fluorescence, while maintaining their ability to exclude the vital dye 7-aminoactinomycin D. Furthermore, monocytes exhibited changes in light scatter patterns that were consistent with apoptosis; these included decreased forward light scatter and increased side scatter. The percentage of cells undergoing apoptosis was dependent upon the mercury content of the medium, regardless of whether the metal was present as methyl, ethyl or phenyl mercury. Mercury-treated cells also exhibited changes in lipid organization within the plasma membrane as evidenced by increased uptake of the fluorescent probe, merocyanine 540, and by elevated annexin V binding to phosphatidylserine. Using the fluorescent probes DiOC6(3) and rhodamine 123 we noted that within 1 h of exposure to mercury, monocytes exhibited a decrease in mitochondrial transmembrane potential (psi m). Since a decreased psi m is associated with altered mitochondrial function, the hypothesis that mercury potentiated reactive oxygen species (ROS) generation and that these species promoted apoptosis was tested. We noted that treated cells generated ROS, as evidenced by oxidation of hydroethidine and the generation of the fluorescent product, ethidium. Finally, since ROS would also lower monocyte reductive reserve, we also measured GSH levels in mercury-treated cells. Chemical measurement of GSH indicated that there was thiol depletion. We suggest that the low thiol reserve predisposes cells to ROS damage and at the same time activates death-signaling pathways.

1 May 1999 in Toxicology and Applied Pharmacology
Verified
Journal Article
Open access
BSBruce J. Shenker
Bruce J. Shenker
TGTai L. Guo
Tai L. Guo
IOInSug O-Sullivan
InSug O-Sullivan
ISIrving M. Shapiro
Irving M. Shapiro
The objective of our study was to define the mechanism by which MeHgCl induces human T-cell apoptosis. We asked the question: does mercury disrupt the Deltapsim and induce a mitochondrial permeability transition state? Using two fluorescent reagents, JC-1 and DiOC6(3), we demonstrated that MeHgCl exposure resulted in a decrease in the Deltapsim. Since a decline in Deltapsim can disturb the pHi, we employed SNARF-1 to assess pHi; results indicate that mercury treatment reduced the pHi from 7.0 to 6.5. Consistent with these observations, we noted that uncoupled electron transfer reactions generated ROS, while cardiolipin, a mitochondrial phospholipid, was oxidized. In concert with the biochemical changes, there was a decrease in overall dimension of the mitochondria of mercury-treated cells and a loss in cristae architecture. The toxicant also depleted the thiol reserves of the cell and promoted translocation of cytochrome c from the mitochondria to the cytosol. Furthermore, when T cells were thiol-depleted, there was increased susceptibility to MeHgCl-induced apoptosis. Finally, we established a temporal relationship between the decline in Deltapsim, generation of ROS, and depletion of thiol reserves. The earliest detectable event was at the level of the mitochondrion; in the presence of MeHgCl there was a profound reduction in mitochondrial Deltapsim and a decline in GSH levels within 1 h. Subsequently, a further decrease in thiol reserves was linked to the generation of ROS. We propose that the target organelle for MeHgCl is the mitochondrion and that induction of oxidative stress leads to activation of death-signaling pathways.

1 July 1999 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
TKThomas Kieber-Emmons
Thomas Kieber-Emmons
PLPing Luo
Ping Luo
JQJianping Qiu
Jianping Qiu
TCTylis Y. Chang
Tylis Y. Chang
IOInSug O-Sullivan
InSug O-Sullivan
ZSZenon Steplewski
Zenon Steplewski